Anzeige
Mehr »
Login
Mittwoch, 24.04.2024 Börsentäglich über 12.000 News von 688 internationalen Medien
SolarBank - Solarenergie… Die einmalige Gelegenheit in diesem Jahrzehnt
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
321 Leser
Artikel bewerten:
(2)

HBK Investments LP - Form 8.3 - Horizon Therapeutics Plc

HBK Investments LP - Form 8.3 - Horizon Therapeutics Plc

PR Newswire

Ap27

FORM 8.3

IRISH TAKEOVER PANEL

OPENING POSITION DISCLOSURE/DEALING DISCLOSURE UNDER RULE 8.3 OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER

RULES, 2022 BY PERSONS WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE

1. KEY INFORMATION

(a) Full name of discloserHBK Investments L.P. on behalf of itself, its subadvisors and its managed funds
(b) Owner or controller of interests and shortpositions disclosed, if different from 1(a)
The naming of nominee or vehicle companies isinsufficient. For a trust, the trustee(s), settlor andbeneficiaries must be named.
N/A
(c) Name of offeror/offeree in relation to whoserelevant securities this form relates
Use a separate form for each offeror/offeree
Horizon Therapeutics Plc
(d) If an exempt fund manager connected with anofferor/offeree, state this and specify identityof offeror/offeree (Note 1)
(e) Date position held/dealing undertaken
For an opening position disclosure, state thelatest practicable date prior to the disclosure
1 February 2023
(f) In addition to the company in 1(c) above, is thediscloser also making disclosures in respectof any other party to the offer?
If it is a cash offer or possible cash offer, state"N/A"
N/A

2. INTERESTS AND SHORT POSITIONS

If there are interests and short positions to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2 for each additional class of relevant security.

Ap28

Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing (if any)

(Note 2)

Class of relevant security
(Note 3)
$0.0001 ordinary shares
InterestsShort positions
Number%Number%
(1) Relevant securities owned and/or controlled5,900,0002.58%
(2) Cash-settled derivatives
(3) Stock-settled derivatives(including options) andagreements to purchase/sell288,8000.13%125,0000.05%
Total6,188,8002.71%125,0000.05%

All interests and all short positions should be disclosed.

Details of options including rights to subscribe for new securities and any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8.

3. DEALINGS (IF ANY) BY THE PERSON MAKING THE DISCLOSURE (Note 4)

Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 3(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.

The currency of all prices and other monetary amounts should be stated.

(a) Purchases and sales

Class of relevant
security
Purchase/saleNumber of
securities
Price per unit
(Note 5)

Ap29

(b) Cash-settled derivative transactions

Class of
relevant
security
Product
description
e.g. CFD
Nature of dealing
e.g. opening/closing a long/short position,increasing/ reducing a long/ short position
Number of
reference
securities
(Note 6)
Price
per unit
(Note 5)

(c) Stock-settled derivative transactions (including options)

(i) Writing, selling, purchasing or varying

Class of
relevant
security
Product
descriptione.g. call
option
Writing,purchasing,selling,varying
etc.
Number
of
securities
to which
option
relates
(Note 6)
Exercise
price per

unit
Type
e.g.
American,
European
etc.
Expiry
date
Option
money
paid/

receivedper unit
$0.0001 ordinary sharesPut OptionWriting41,100USD 109American17 February 2023USD 0.2281
$0.0001 ordinary sharesPut OptionWriting47,700USD 109American17 February 2023USD 0.2282
$0.0001 ordinary sharesPut OptionWriting100,000USD 109American17 February 2023USD 0.25
$0.0001 ordinary sharesCall OptionWriting25,000USD 112American17 February 2023USD 0.1628
$0.0001 ordinary sharesCall OptionWriting100,000USD 112American17 February 2023USD 0.25

(ii) Exercise

Class of
relevant
security
Product
description
e.g. call
option
Exercising/
exercised
against
Number of
securities
Exercise
price per
unit
(Note 5)

(d) Other dealings (including transactions in respect of new securities) (Note 3)

Class of
relevant
security
Nature of dealing
e.g. subscription,
conversion, exercise
DetailsPrice per unit (if
applicable)
(Note 5)

Ap30

4. OTHER INFORMATION

(a) Indemnity and other dealing arrangements

Details of any indemnity or option arrangement, or any agreementor understanding, formal or informal, relating to relevant securitieswhich may be an inducement to deal or refrain from dealingentered into by the person making the disclosure and any party tothe offer or any person acting in concert with a party to the offer.
Irrevocable commitments and letters of intent should not be included. Ifthere are no such agreements, arrangements or understandings, state"none"
None

(b) Agreements, arrangements or understandings relating to options or derivatives

Full details of any agreement, arrangement or understandingbetween the person disclosing and any other person relatingto the voting rights of any relevant securities under any optionreferred to on this form or relating to the voting rights or futureacquisition or disposal of any relevant securities to which anyderivative referred to on this form is referenced. If none, thisshould be stated.
None

(c) Attachments

Is a Supplemental Form 8 attached?Yes

Date of disclosure2 February 2023
Contact nameJonathan Brown
Telephone number+44 (0)20 7659 1906

Public disclosures under Rule 8.3 of the Rules must be made to a Regulatory Information Service.

Ap31

Ap32

SUPPLEMENTAL FORM 8

IRISH TAKEOVER PANEL

DISCLOSURE UNDER RULE 8.1, RULE 8.3, RULE 38.5(b) AND
RULE 38.6 OF THE IRISH TAKEOVER PANEL ACT, 1997,
TAKEOVER RULES, 2022

DETAILS OF OPEN STOCK-SETTLED DERIVATIVE (INCLUDING
OPTION) POSITIONS, AGREEMENTS TO PURCHASE OR SELL AND
RIGHTS TO SUBSCRIBE FOR NEW SECURITIES

1. KEY INFORMATION

Full name of person making
disclosure:
HBK Investments L.P. on behalf of itself, its subadvisors and its managed funds
Name of offeror/offeree in relation
to whose relevant securities the
disclosure relates:
Horizon Therapeutics Plc

2. STOCK-SETTLED DERIVATIVES (INCLUDING OPTIONS)

Class of
relevant
security
Product
description
e.g. call
option
Written or
purchased
Number of
securities to
which option
or derivative

relates
Exercise
price
per unit
Type
e.g.
American,
European
etc.
Expiry
date
$0.0001 ordinary shares Put optionWritten53,700USD 109American17 February 2023
$0.0001 ordinary shares Put optionWritten46,300USD 109American17 February 2023
$0.0001 ordinary shares Put optionWritten41,100USD 109American17 February 2023
$0.0001 ordinary shares Put optionWritten47,700USD 109American17 February 2023
$0.0001 ordinary shares Put optionWritten100,000USD 109American17 February 2023
$0.0001 ordinary shares Call optionWritten25,000USD 112American17 February 2023
$0.0001 ordinary shares Call optionWritten100,000USD 112American17 February 2023

3. AGREEMENTS TO PURCHASE OR SELL

Full details should be given so that the nature of the interest orposition can be fully understood:

Ap33

4. RIGHTS TO SUBSCRIBE FOR NEW SECURITIES (INCLUDING DIRECTORS' AND OTHER EMPLOYEE OPTIONS)

Class of relevant security inrelation to which subscriptionright exists:
Details, including nature of therights concerned and relevantpercentages:

It is not necessary to provide details on a Supplemental Form with regard to cash-settled derivatives.

The currency of all prices and other monetary amounts should be stated.

For full details of disclosure requirements, see Rule 8 of the Rules. If in doubt, consult the Panel.

References in these notes to "the Rules" are to the Irish Takeover Panel Act, 1997, Takeover Rules, 2022.

Großer Insider-Report 2024 von Dr. Dennis Riedl
Wenn Insider handeln, sollten Sie aufmerksam werden. In diesem kostenlosen Report erfahren Sie, welche Aktien Sie im Moment im Blick behalten und von welchen Sie lieber die Finger lassen sollten.
Hier klicken
© 2023 PR Newswire
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.